Open Access
06-03-2024 | Gefitinib | Case Report - Molecularly targeted therapy
EGFR-mutated lung adenocarcinoma with choroidal oligometastasis during treatment with gefitinib: a case report
Authors:
Takafumi Hashimoto, Atsushi Osoegawa, Miyuki Abe, Ryoko Oki, Takashi Karashima, Yohei Takumi, Kosuke Kamada, Michiyo Miyawaki, Kenji Sugio
Published in:
International Cancer Conference Journal
Login to get access
Abstract
The patient was a 74-year-old woman who was diagnosed with lung adenocarcinoma, clinical Stage IIIA. Induction chemoradiation was performed followed by right upper lobectomy and lymph node dissection. Because of positive pleural effusion cytology, which was proven after surgery, the patient was diagnosed with pathological Stage IVA with EGFR L858R mutation. At 17 months after the administration of gefitinib, left choroidal metastasis appeared. Stereotactic irradiation and ruthenium small-beam radiation were effective; however, the metastatic lesion showed regrowth 7 months after these treatments. Because the patient’s choroidal oligometastasis was resistant to conservative therapy, left ophthalmectomy was performed. EGFR mutations (L858R and E709K) were detected in the resected choroidal tumor. The patient continued to take gefitinib. However, a neoplastic lesion developed on the optic nerve adjacent to the resected posterior eye segment. The lesion was treated with stereotactic radiation, gefitinib was switched to afatinib 30 mg, and the patient remains alive and disease free for 11 months.